CA-XSOLLA/GDC
21.3.2022 12:02:11 CET | Business Wire | Press release
Xsolla , a global video game commerce company, is attending and presenting at GDC (Game Developers Conference) , the biggest game conference in the world, today through March 25th in San Francisco, California, USA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220321005435/en/
Xsolla is hosting six informative speaking sessions on Tuesday, March 22nd, including a keynote from President Chris Hewish. Additionally, Xsolla is exhibiting at Moscone South S657, starting on Wednesday, March 23rd, where attendees can meet with Xsolla experts and get a preview of the latest products and solutions designed to accelerate video game commerce in 2022.
“I’m excited to return to GDC in person and to kick off Xsolla’s series of trending topic speaker sessions,” Hewish said. “It’s great to see old friends and meet new people from all over the world who share our passion for video games.”
The Xsolla team is sharing industry updates and their expertise on the tools and services available for video game developers and publishers. Topics will range from mobile game monetization outside of the app store, payments for the enterprise , and token-based systems for digital content with a new NFT Checkout to emerging market opportunities and prelaunch funding . Video-on-demand of the sessions will be available later in the week for those who could not attend to watch and learn.
Tuesday, March 22 | 9:30am - 10:30am [Add to iCal
]
GOING GLOBAL, STAYING LOCAL: HELPING GAME DEVELOPERS SUCCEED
Great games don’t just appear. They start as ideas, and only through the curiosity, dedication, and grit of people all over the globe do they come to life. Xsolla President Chris Hewish outlines ways to ensure that every developer has the same opportunity to see their game become a part of how we play.
Tuesday, March 22 | 10:50am - 11:50am [Add to iCal
]
INSIDE THE WALLED PAYMENT GARDEN: A GUIDE TO MOBILE MARKET FREEDOM
In this session, Anthony Mendoza and Miikka Luotio share a frank discussion on how developers can break into mobile gaming's 'walled payment garden' and grow their games just as many others have already done.
Tuesday, March 22 | 1:20pm - 1:50pm [Add to iCal
]
GAME OF FUNDS: SUCCESS IS COMING
Xsolla’s dynamic duo of funding, Justin Berenbaum and Lily Goldner, host special guests David Martinez from Raw Fury and Ken Seto from Massive Damage Games in a fireside chat, where you’ll discover how to improve your chances and create business alliances.
Tuesday, March 22 | 2:10pm - 2:40pm [Add to iCal
]
BEYOND CREDIT: TAKING ADVANTAGE OF EMERGING PAYMENT METHODS
WORLDWIDE
"Cash, check or charge?" It used to be that these were the only options when handling payments. Now there are hundreds. Berkley Egenes leads a team of Xsolla regional experts as they discuss how to control the chaos and take advantage of emerging payment methods around the globe.
Tuesday, March 22 | 3:00pm - 3:30pm [Add to iCal
]
"THINGS I WISH I KNEW SOONER" ABOUT THE GAME INDUSTRY
Xsolla's Sam Gaglani hosts a panel of games industry pros, including Kara Bilkiss from Rogue Games, Michael Lewis from Take-Two Interactive, and Andreea Enache from Secret Society Games who've "been there, done that" as they share their wisdom and insights. They will focus on topics that affect developers at any studio and discuss things they wish they had known sooner about working in the industry.
Tuesday, March 22 | 3:50pm - 4:20pm [Add to iCal
]
HYBRID TIMES: GAME DEVELOPERS SOUND OFF ON WORKING FROM HOME, COMPENSATION, AND CAREER
The industry-leading platform 80 Level asked the gaming community about recent challenges and opportunities, and over 800 game developers shared their experiences. Kirill Tokarev, Editor in Chief at 80 Level, highlights what these responses reveal about our past and what the future has in store.
Book a meeting with Xsolla’s global game commerce experts to discover how they can help expand your video game commerce in the changing games industry.
For more information on how to attend speaking sessions and connect with Xsolla at GDC 2022, visit https://xsolla.com/gdc2022
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes to promote and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing and monetization to help our partners reach more geographies, generate more revenue and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Berlin, Seoul, and cities around the world to support major gaming titles like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more. For additional information and to learn more, please visit xsolla.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005435/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom